IDO expression in the brain: a double-edged sword - PubMed (original) (raw)
Review
. 2007 Dec;85(12):1351-9.
doi: 10.1007/s00109-007-0229-7. Epub 2007 Jun 27.
Affiliations
- PMID: 17594069
- DOI: 10.1007/s00109-007-0229-7
Review
IDO expression in the brain: a double-edged sword
Erik Kwidzinski et al. J Mol Med (Berl). 2007 Dec.
Abstract
The tryptophan-catabolizing enzyme indoleamine-2,3-dioxygenase (IDO) initiates the first and rate-limiting step of the kynurenine pathway. It is induced by proinflammatory cytokines such as interferon-beta and interferon-gamma and has established effects in the control of intracellular parasites. The recent detection of its decisive function in immune tolerance at the maternal-fetal interface stimulated various studies unraveling its regulatory effect on T cells in many pathologies. In the brain, IDO can be induced in microglia by interferon-gamma-producing T helper (Th) 1 cells, thereby initiating a negative feedback loop which downmodulates neuroinflammation in experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS). This protective effect could to be counteracted by the production of neurotoxic metabolites of the kynurenine pathway such as quinolinic acid, which are produced upon IDO induction. Some metabolites of the kynurenine pathway can pass the blood-brain barrier and thus could act as neurotoxins, e.g., during systemic infection. In this paper, we give a brief overview on established immune regulatory functions of IDO, review recent data on IDO expression in the brain, and propose that autoimmune neuroinflammation and the increasingly appreciated neuronal damage in MS are linked by Th1-mediated IDO induction through subsequent synthesis of toxic metabolites of tryptophan.
Similar articles
- Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Zarzecki MS, Cattelan Souza L, Giacomeli R, Silva MRP, Prigol M, Boeira SP, Jesse CR. Zarzecki MS, et al. Neurochem Res. 2020 Dec;45(12):2959-2977. doi: 10.1007/s11064-020-03144-6. Epub 2020 Oct 11. Neurochem Res. 2020. PMID: 33040279 - Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation.
Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I. Kwidzinski E, et al. FASEB J. 2005 Aug;19(10):1347-9. doi: 10.1096/fj.04-3228fje. Epub 2005 Jun 6. FASEB J. 2005. PMID: 15939737 - IDO: a double-edged sword for T(H)1/T(H)2 regulation.
Xu H, Zhang GX, Ciric B, Rostami A. Xu H, et al. Immunol Lett. 2008 Nov 16;121(1):1-6. doi: 10.1016/j.imlet.2008.08.008. Epub 2008 Sep 29. Immunol Lett. 2008. PMID: 18824197 Free PMC article. Review. - Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
Myint AM, Kim YK. Myint AM, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:304-13. doi: 10.1016/j.pnpbp.2013.08.008. Epub 2013 Oct 31. Prog Neuropsychopharmacol Biol Psychiatry. 2014. PMID: 24184687 Review.
Cited by
- Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals.
Keegan MR, Chittiprol S, Letendre SL, Winston A, Fuchs D, Boasso A, Iudicello J, Ellis RJ. Keegan MR, et al. Int J Tryptophan Res. 2016 Oct 26;9:79-88. doi: 10.4137/IJTR.S36464. eCollection 2016. Int J Tryptophan Res. 2016. PMID: 27812290 Free PMC article. - Immunopathological Factors Associated with Disability in Multiple Sclerosis.
Tüzün E. Tüzün E. Noro Psikiyatr Ars. 2018;55(Suppl 1):S26-S30. doi: 10.29399/npa.23303. Noro Psikiyatr Ars. 2018. PMID: 30692851 Free PMC article. Review. - Increased Indoleamine 2,3-Dioxygenase and Quinolinic Acid Expression in Microglia and Müller Cells of Diabetic Human and Rodent Retina.
Hu P, Hunt NH, Arfuso F, Shaw LC, Uddin MN, Zhu M, Devasahayam R, Adamson SJ, Benson VL, Chan-Ling T, Grant MB. Hu P, et al. Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5043-5055. doi: 10.1167/iovs.17-21654. Invest Ophthalmol Vis Sci. 2017. PMID: 28980000 Free PMC article. - Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.
Gendelman HE, Zhang Y, Santamaria P, Olson KE, Schutt CR, Bhatti D, Shetty BLD, Lu Y, Estes KA, Standaert DG, Heinrichs-Graham E, Larson L, Meza JL, Follett M, Forsberg E, Siuzdak G, Wilson TW, Peterson C, Mosley RL. Gendelman HE, et al. NPJ Parkinsons Dis. 2017 Mar 23;3:10. doi: 10.1038/s41531-017-0013-5. eCollection 2017. NPJ Parkinsons Dis. 2017. PMID: 28649610 Free PMC article. - Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway.
Török N, Tanaka M, Vécsei L. Török N, et al. Int J Mol Sci. 2020 Dec 8;21(24):9338. doi: 10.3390/ijms21249338. Int J Mol Sci. 2020. PMID: 33302404 Free PMC article. Review.
References
- J Neural Transm Suppl. 2003;(65):29-49 - PubMed
- Cancer Res. 2005 Sep 15;65(18):8065-8 - PubMed
- Science. 2002 Sep 13;297(5588):1867-70 - PubMed
- J Biochem. 2006 Apr;139(4):655-62 - PubMed
- Infect Immun. 1994 Sep;62(9):3705-11 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials